期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
加味紫归油滴鼻治疗干燥性鼻炎的临床研究
1
作者 刘真 石颖 +3 位作者 刘昱辛 陈策 戴璐璐 刘静 《中国中西医结合耳鼻咽喉科杂志》 2023年第6期413-417,共5页
目的观察“加味紫归油”滴鼻治疗干燥性性鼻炎的临床疗效。方法就诊于中国中医科学院西苑医院耳鼻喉科的干燥性性鼻炎患者120例,采用随机数字表法随机分为三组,治疗A组即加味紫归油组(60例),阳性药物对照B1组即复方薄荷油组(30例),基质... 目的观察“加味紫归油”滴鼻治疗干燥性性鼻炎的临床疗效。方法就诊于中国中医科学院西苑医院耳鼻喉科的干燥性性鼻炎患者120例,采用随机数字表法随机分为三组,治疗A组即加味紫归油组(60例),阳性药物对照B1组即复方薄荷油组(30例),基质对照B2组即香油组(30例),每日早晚各1次滴鼻,每次每鼻孔2滴,疗程1周,治疗前后分别对三组患者进行干燥性鼻炎症状体征分级评分、视觉模拟量表(VAS)评分,记录入组患者药物起效时间,入组1月时复发情况,记录试验期间不良反应,对“加味紫归油”的临床疗效进行评价。结果共有114例患者完成试验,经加味紫归油治疗后患者VAS评分、干燥性鼻炎症状体征分级量化评分均较入组时明显下降,VAS量表治疗前后各项评分的差异比较均具有统计学意义(P<0.05),症状体征分级量化评分在改善鼻干燥感、涕中带血、鼻腔黏膜、鼻腔痂皮、利特区黏膜糜烂方面,分值变化均优于两组对照组,具有统计学意义(P<0.05)。结论加味紫归油治疗干燥性鼻炎起效快,疗效确切。 展开更多
关键词 加味紫归油 干燥性鼻炎 外治法 滴鼻
下载PDF
Moxibustion versus non-moxibustion for immune reconstitution inflammatory syndrome in patients with HIV:A 48-week prospective cohort study
2
作者 Guo-jian GAO Hui-jun GUO +10 位作者 Xin LI Yao-kai CHEN Xing-hua TAN Yu-qi YANG Jian-ping MA Shui-qing LIU Quan-sheng FENG Wen ZOU Ji-peng DONG Jian WANG Ying LIU 《World Journal of Acupuncture-Moxibustion》 CAS CSCD 2024年第4期318-324,共7页
Objective:To assess the effects of moxibustion on immune reconstitution inflammatory syndrome(IRIS)in patients with acquired immune deficiency syndrome(AIDS)by tracking T-cell subsets over a 48-week prospective cohort... Objective:To assess the effects of moxibustion on immune reconstitution inflammatory syndrome(IRIS)in patients with acquired immune deficiency syndrome(AIDS)by tracking T-cell subsets over a 48-week prospective cohort study.Methods:Patients with AIDS who had low viral loads and weakened immune systems were divided into a moxibustion group and a non-moxibustion group.The non-moxibustion group received standard western treatment,including 48 weeks of antiretroviral therapy(ART).The moxibustion group received ART combined with moxibusion therapy,administered three times weekly.Each treatment lasted 10 weeks,with four courses completed over 48 weeks,separated by 2-week breaks.At different time points,plasma levels of CD4^(+),CD8^(+),CD45RAt,CD45RO^(+),CD4^(+)CD28^(+),CD8^(+)CD38^(+),and CD4^(+)CD38^(+)were compared between the two groups.Results:A total of 200 eligible patients were included and divided into two groups,with 100 in the non-moxibustion group and 100 in the moxibustion group.At Week 24,the CD4^(+)T cell count was(180.71±79.62)cells/μL in the non-moxibustion group and(218.22±82.02)cells/μL in the moxibustion group.By Week 36,the counts were(204.83±96.78)cells/μuL and(239.35±81.90)cells/μL,respectively.At Weeks 24 and 48,the CD8^(+)T cell and CD45RO^(+)counts were higher in the moxibustion group than in the non-moxibustion group(P<0.05).By Week 48,the CD45RA^(+)count was also higher in the moxibustion group(P<0.05).At Week 24,the CD4^(+)CD25^(+)count was lower in the moxibustion group than in the non-moxibustion group(P<0.05). 展开更多
关键词 Acquired immune deficiency syndrome MOXIBUSTION Antiretroviral therapy T cell subset
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部